Climb Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Director and Officer Trading Arrangements
The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended December 31, 2025, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (“Rule 10b5-1 Plan”), were as follows:
| Name (Title) | Action taken(Date of Action) | Type of Trading Arrangement | Nature of TradingArrangement | Duration of TradingArrangement | Aggregate Numberof Securities |
|---|---|---|---|---|---|
| Stephen Thomas(Director) | Adoption(October 14, 2025) | Rule 10b5-1 trading arrangement | Sale | Until August 8, 2026, or, if earlier, upon the completed sale of the maximum shares | 150,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.